You are here

Orphazyme

Drug Development for Rare Diseases is Littered with Regulatory Roadblocks

BioSpace

Fri, 08/19/22 - 10:41 am

drug development

Orphazyme agrees to sell itself, and its 'pipeline-in-a-product,' to KemPharm

Endpoints

Mon, 05/16/22 - 10:20 am

Orphazyme on last leg as court-mediated restructuring drives another wave of layoffs

Fierce Biotech

Thu, 03/10/22 - 10:29 pm

FDA rejection of rare disease drug leads Orphazyme to cut two thirds of staff

MedCity News

Tue, 06/29/21 - 10:55 am

Niemann-Pick disease

FDA rejects Orphazyme's rare disease drug, continuing wild ride for Danish meme stock

Fierce Biotech

Fri, 06/18/21 - 10:17 am

Niemann-Pick disease

FDA Action Alert: Blueprint, Orphazyme and Eton

BioSpace

Mon, 06/14/21 - 10:52 am

Blueprint Medicines

Eton Pharmaceuticals

The "Rare Disease Company Coalition" Launches to Share the Unique Challenges and Promise of Rare Disease Therapy Development to Support Continued Progress and Patient Access

Yahoo/Businesswire

Thu, 05/13/21 - 12:04 pm

Rare Disease Company Coalition

drug development

Aeglea BioTherapeutics

Agios Pharmaceuticals

Harmony Biosciences

Orchard Therapeutics

Sarepta Therapeutics

Taysha Gene Therapies

Second-quarter catalysts for the smaller players

EP Vantage

Wed, 04/7/21 - 10:25 am

Fulcrum Therapeutics

Gemini Therapeutics

Orphazyme shares sink as late-stage test of 'heat shock protein' flops

Fierce Biotech

Mon, 03/29/21 - 10:33 am

heat shock protein

inclusion body myositis

clinical trials

Nearly two years after their narrow PhIII failure, Orphazyme gets speedy look at the FDA

Endpoints

Wed, 09/16/20 - 10:38 am

clinical trials

Niemann-Pick disease

Cytrx: Another Stride Ensuring Continued Shareholder Value

Seeking Alpha

Wed, 05/18/11 - 11:43 am

CytRx touts "game changing" $120M pact with Orphazyme

Fierce Biotech

Tue, 05/17/11 - 01:08 pm